Clinical Trial Update: Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017) [Phase 3]

View source ↗

Summary

Phase 3 safety and immunogenicity study of GARDASIL 9 (V503) in 9- to 26-year-old females and males in Vietnam has completed enrollment with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma in Situ
• Condylomata Acuminata
• Papillomavirus Infections
• Uterine Cervical Neoplasms
• Vaginal Neoplasms
• Vulvar Neoplasms

Drugs mentioned

• Gardasil 9 (Human papillomavirus vaccine, 9-valent)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Papillomavirus Infections, Uterine Cervical Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2020-02-05